Cantor Fitzgerald Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $132.00 (from $135.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $94.87 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Amcor Plc. (AMCR) to Neutral
- Goldman Sachs Upgrades Lonking Holdings Limited (3339:HK) (LONKF) to Buy
- RWE (RWE:GR) (RWNFF) PT Raised to EUR65 at Deutsche Bank
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
